Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of progression to active multiple myeloma or death ...

Researchers have launched a new open-source MATLAB toolbox that generates synthetic networks with built-in vital nodes, providing a standardized ...

The line between groundbreaking technology and a passing fad is often drawn by a single factor: the ability to solve ...